Main Menu

Professor Nick Turner

Group Leader

The alt text
Professor Nicholas Turner is an Academic Consultant Medical Oncologist who specialises in breast cancer treatment. He is a Group Leader in the Breast Cancer Now Toby Robins Research Centre and Chief Investigator of many national and international trials of personalised breast cancer therapy. Group: Molecular Oncology
+44 20 7153 5574 ORCID 0000-0001-8937-0873

Biography

Professor Nicholas Turner is an Academic Consultant Medical Oncologist who specialises in the treatment of breast cancer.

He is a Group Leader in the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London.

See all news stories on our website that feature the work of Professor Turner and colleagues.

Read news

Professor Turner read Natural Sciences at Cambridge University before qualifying in 1997 from the University of Oxford Medical School.

After completing general medical training in London, he trained in Medical Oncology at The Royal Free and University College Hospital and completed a PhD at the ICR in 2006.

He joined the Breast Unit of The Royal Marsden and the ICR as a Senior Lecturer and Honorary Consultant in Medical Oncology in 2008.

He is a Cancer Research UK Clinician Scientist Fellow and devotes the majority of his time to academic research, both in the laboratory investigating novel therapies for the treatment of breast cancer and in clinical trial research.

Professor Turner is Chief Investigator of a number of national and international trials of personalised therapy in Breast Cancer. He is Deputy Editor of the journal Breast Cancer Research, Breast Theme lead for The Royal Marsden National Institute for Health Research Biomedical Research Centre, and on the organizing committees of many international conferences on breast cancer.

Professor Turner is a member of the Cancer Research UK Convergence Science Centre, which brings together leading researchers in engineering, physical sciences, life sciences and medicine to develop innovative ways to address challenges in cancer.

Convergence Science Centre